GuideHaematology
IPI24 in diffuse large B-cell lymphoma
Model estimating the individual probability of failing to achieve 24-month event-free survival (EFS24) in DLBCL.
Updated 3 November 2026
When to use it
At diagnosis of DLBCL to be treated with anthracycline-based immunochemotherapy (R-CHOP-like).
What it is
Maurer et al. (2016) developed IPI24 in 1,348 patients and validated it independently in 1,177. It returns an individual probability of EFS24 failure instead of the four IPI groups.
Keep reading in the app
- Variables
- How to interpret it
- Limitations
Practical tip
Reaching EFS24 matters: those who do have subsequent survival similar to the age- and sex-matched general population.
2 more practical tips in the app.
Reference
A support tool for healthcare professionals: it guides and does not replace clinical judgement.
